2.Report on recent discontinuation of tyrosine kinase inhibitors and alternative approaches to eradicating the chronic myeloid leukemia stem cells in the 55th ASH annual meeting
Journal of Leukemia & Lymphoma 2014;23(1):12-16
Tyrosine kinase inhibitor (TKI) may significantly improve the treatment outcome in chronic myeloid leukemia (CML).It is the most frequent question about whether the patients with durable complete molecular response (CMR) can safely discontinue TKI treatment without relapse.This has focused attention on the strategies to eradicate residual CML cells,especially the CML stem cells,which should result in long term leukemia-free survival and permanent cure.Here,the progress on discontinuation of TKI therapy and alternative approaches to eradicating CML stem cells in the 55th ASH annual meeting is reviewed.
3.Umbilical cord mesenchymal stem cell transplantation for liver cirrhosis: a repeated measurement analysis
Chinese Journal of Tissue Engineering Research 2015;19(19):3027-3031
BACKGROUND:The research for mesenchymal stem cels in the treatment of liver cirrhosis has made great progress. However,t-test analysis is often misused in clinical practice. OBJECTIVE:To analyze the efficacy and safety of umbilical cord mesenchymal stem cel therapy for liver cirrhosis by repeated measurement method. METHODS: A total of 27 patients with decompensated liver cirrhosis underwent conventional medical treatments, including liver protection treatment and symptomatic treatment. At 1 week after hospitalization, patients were given intravenous transplantation of umbilical cord mesenchymal stem cels (passages 2-4), cel viability≥ 90%, stem cel counting≥ 2×107 cels, four times with an interval of 5-7 days. Analysis of variance based on repeated measurement data was performed to analyze the liver function changes at different time after umbilical cord mesenchymal stem cel transplantation. RESULTS AND CONCLUSION: The results of univariate repeated measurement showed that at 2 and 3 months after treatment, the serum albumin level was increased and the total bilirubin level in serum was decreased significantly (P < 0.05); at 3 months after treatment, the content of aspartate aminotransferase decreased, and the content of cholinesterase increased significantly (P < 0.05). No patient appeared to have liver and other organ tumors during the observation period. These findings indicate that umbilical cord mesenchymal stem cel transplantation is effective and safe in the treatment of liver cirrhosis, which can significantly improve patient's liver functions.
4.Effects of oxidized HDL on the levels of MCP-1, ICAM-1 and free calcium in cultured human umbilical venous endothelial cells
Chinese Journal of Pathophysiology 2001;17(6):559-562
AIM: To study the effects of oxidized high-density lipoprotein (oxHDL) on the expression of monocyte chemoattractant protein-1(MCP-1) and intercellular adhesion molecule-1(ICAM-1) and intracellular free calcium concentration ([Ca2+]i) level in cultured human umbilical venous endothelial cells(HUVECs). METHODS: The MCP-1 protein content in the medium of conditioned HUVEC was measured by ELISA, and the ICAM-1 on HUVECs was detected by indirect immunofluorescence, and [Ca2+]i was determined by Fluo-3/AM, the injury of cells was observed by scanning electron microscopy (SEM).RESULTS: oxHDL could induce the expression of MCP-1 and ICAM-1 in HUVECs. In oxHDL group (HUVECs were incubated with 100 mg protein/L oxHDL for 24 h), the levels of MCP-1, ICAM-1 and [Ca2+]i increased by 160%, 60% and 70% respectively compared with the control group (P<0.01). When HUVECs were incubated with 300 mg protein/L oxHDL for 24 h, cells were injured obviously. CONCLUSION: By inducing the expression of ICAM-1 and MCP-1 in endothelial cells, oxHDL may promote monocyte-endothelium adhesion and monocyte migration to intima, it may promote atherosclerosis as oxidized low-density lipoprotein (oxLDL).
5.Combined application of TBL with LBL in immunology experiment teaching
Chinese Journal of Medical Education Research 2014;(6):618-621
Objective This article made an exploration on the feasibility of combined applica-tion of TBL with LBL in immunology experiment teaching, and analyzed teaching effectiveness of such combined model in order to find a new way of teaching reformation. Methods 2012 grade biophar-maceutical technology students were chosen in this research, one class as the experimental group(n=42), the other one as control group(n=42). In the experimental group, students were taught on a TBL+LBL combination model, while in the control group, students were taught only on LBL model. After the course was finished, effects of teaching were evaluated by questionnaire survey and compre-hensive ability evaluation. SPSS 18.0 software was used to do statistical analysis. Quantitative data and qualitative data were analyzed by t test and chi-square test respectively. P<0.05 means that difference is statistically significant. Results Above 90.0% of students in experiment group approved that TBL+LBL can improve the interest in learning , can enhance sense of teamwork , can help acquiring of knowledge and improving of individual comprehensive ability. Average score of comprehensive ability evaluation and percentage of students achieving good score in experimental group were higher than those in control group, the differences were statistically significant(t=2.020, P=0.049; χ2=6.372, P=0.012). Conclusion The TBL+LBL combination model can improve immunology experiment teach-ing quality, and is worth publicizing.
7.The level and clinical significance of serum anti-lysosomal associated membrane protein-2 antibody in patients with ANCA-associated glomerulonephritis
Chinese Journal of Nephrology 2014;30(7):494-498
Objective To investigate the relationship of the serum anti-lysosome associated membrane protein 2 (LAMP-2) antibody levels and anti-neutrophil cytoplasmic antibodies (ANCA)-associated glomerulonephritis.Methods Thirty-three patients with new onset ANCA-associated glomerulonephritis and thirty healthy controls were enrolled.ANCA detection was performed using indirect immunofluorescence (IIF).Enzyme-linked immunosorbent assay (ELISA) was used to detect myeloperoxidase (MPO),proteinase-3 (PR3) and other ANCA-associated antibodies including LAMP-2.The cut-off value of the serum anti-LAMP-2 antibody was determined by a receiver operating characteristic (ROC) curve.Results The serum levels of anti-LAMP-2 antibody in new onset ANCA-associated glomerulonephritis patients were significantly higher than remission stage ANCA-associated glomerulonephritis patients and healthy controls (P < 0.05).The serum levels of anti-LAMP-2 antibody showed no visible difference between the remission ANCA-associated glomerulonephritis patients and healthy controls (P > 0.05).The levels of anti-LAMP-2 antibody showed a strong positive correlation with ESR,Scr,BUN,proteinuria,crescent proportion and Birmingham vasculitis activity score (BVAS) and a negative correlation with Ccr,Hb and Alb.Conclusions Anti-LAMP-2 antibody is correlated with the activity of ANCA-associated glomerulonephritis and the severity of renal damage.It may be a useful indicator on the activity of ANCA-associated glomerulonephritis.
8.Effect of Different Penetration Enhancers on the Transdermal Permeation of Diclofenac Potassium Gel in Vitro
China Pharmacy 2005;0(19):-
OBJECTIVE: To study the effects of Azone,propylene glycol(PG),oleic acid(OA) alone or in combination of two or three as penetration enhancers on the in vitro transdermal efficacy of diclofenac potassium(DP) gels.METHODS: Thirteen formulations of DP gels containing the following different penetration enhancers at different concentrations were prepared: blank,3% Azone, 5% OA,12% PG,6% PG+2.5% OA,12% PG+5% OA,1.5% Azone+2.5% OA,1.5% Azone+6% PG+5% OA,1.5 % Azone+12% PG,3% Azone+5% OA,3% Azone+6% PG,3% Azone+6% PG+5% OA,and 3% Azone+12% PG.The in vitro permeation test was performed on a modified Franz-type diffusion cell with human skin as transdermal barrier taking transdermal velocity(J) as index to determine and compute the transdermal properties of the DP gels after treated respectively by the above 13 penetration enhancers.RESULTS: Compared with the blank control group,all the penetration enhancer-treated formulations showed significant higher J value,with the formulation treated by 3% Az-one+12% PG enhancer showing the highest J value of 10.253 0 ?g?cm-2?h-1.CONCLUSION: All the three penetration enhancers could promote the transdermal permeation DP gels,much as in the combination of Azone and propylene.
9.Analysis of the Medical Cost of Capectabine in Treatment of Advanced Rectocolonic Carcinoma
China Pharmacy 2001;0(07):-
OBJECTIVE:To evaluate the medical cost of capectabine in treatment of advanced rectocolonic carcino?ma.METHODS:The characteristics of therapeutic effect and medical cost were compared between capectabine and classical MAYO program.RESULTS&CONCLUSION:The capectabine is more expensive than traditional drugs,however,in terms of medical resource,the saving medical cost in use of capectabine would counterbalance the expensive price of drug to maxium limit.The medical cost of capectabine is superior to that of traditional drugs.
10.The Cost-Effectiveness Analysis of Irbesartan in the Treatment of Hypertensive Type 2 Diabetic Patients with Microalbuminuria in China
China Pharmacy 1991;0(03):-
OBJECTIVE:To evaluate the cumulative incidence of end-stage renal disease(ESRD)in Chinese hypertensive type2diabetic patients with microalbuminuria(DHM)treated with different regimes,and to provide reference for decision makers.METHODS:A peer-reviewed Markov model that simulated progression from microalbuminuria to nephropathy,dou?bling of serum creatinine,ESRD,and all-cause mortality in patients with DHM was adapted to China.Three strategies were compared:(1)early use of irbesartan(i.e.prompt treatment in subjects with microalbuminuria);(2)late use of irebesartan(i.e.as from overt nephropathy);(3)standard hypertension care(with comparable blood pressure control).Cumulative incidence of ESRD,costs and life expectancy were projected for a hypothetical cohort of1000subjects.Treatment-specific progression and mortality probabilities were derived from published trials:IRMA-2(in microalbuminuria)and IDNT(in overt nephropathy).Medical management and cost data per state were obtained from published local sources.A flexible time horizon up to25years and third party payer perspective were used.Future costs and LE were discounted at3%yearly.RESULTS:When compared with standard blood pressure control,early use of irbesartan was evaluated to reduce the cumulative incidence of ESRD from(mean?standard deviation)8%to22%,save RMB30348(US$3667),and add0.638life years per treated patient.Late use of irbesartan was dominant over control group but dominated by early irbesartan.Break-even occurred after13years.CON?CLUSION:Treating DHM patients by early use of irbesartan is evaluated to reduce the incidence of ESRD,extend life and reduce costs.Treating patients at a later stage is still beneficial,however to a lower extent.